| Literature DB >> 29188158 |
Alice Shen1, Gabriel O Ologun1, Robert Behm2.
Abstract
Clostridium perfringens (CP) bacteremia is a rare but rapidly fatal infection. Only 36 cases of CP bacteremia with gas containing liver abscesses on image studies have been reported in the literature since 1990. In this report, we describe a 65-year-old diabetic male with CP bacteremia which progressed into fulminant hepatic failure with subsequent fatal cerebral edema.Entities:
Keywords: clostridium perfringens; diabetes mellitus; fatal cerebral edema; fulminant liver failure; hepatic abscesses
Year: 2017 PMID: 29188158 PMCID: PMC5703590 DOI: 10.7759/cureus.1714
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1The first endoscopic retrograde cholangiopancreatogram (ERCP) revealing absence of filling defect in the biliary tree (outlined area and arrow).
Figure 2Duodenal diverticulum containing stone.
Figure 3Multiple hepatic abscesses and multiple air fluid levels.
Figure 4Resolution of liver abscess status post-surgical drainage. Outline and arrow indicating area of interest.
Figure 5Severe and diffuse cerebral edema with obstructive hydrocephalus.
Cases of Clostridium perfringens infection associated with gas-containing liver abscesses on image studies published since 1990.
Hb = reported hemoglobin (g/dL); WBC = white blood cell count (K-g/L); TBili = total bilirubin (mg/dL); LDH = Lactate dehydrogenase; M = male; F = female; DM = diabetes mellitus; CBD = common bile duct; CA = cancer; TACE = transarterial chemoembolization; ESRD = end-stage renal disease; HD = hemodialysis; HCC = hepatocellular carcinoma; RY HJ = Roux-en-Y hepatojejunostomy; MW = microwave; Yes-p = percutaneous drainage; Yes- O = operative drainage; BCx = blood culture; Liver Cx= Liver Culture; + = positive for Clostridium perfringens; nr = not reported or not obtained; E. coli = positive for E. coli but negative for Clostridium perfringens; – = negative for C. perfringens; (a) = autopsy; S.c.= positive for Saccharomyces cerevisiae, negative for Clostridium perfringens. Hrs = hours; N/A = does not apply.
References mentioned in this table are available on request.
| No. | Author | Year | Age | Sex | Underlying Conditions(s) | WBC | Hb | TBili | BCx | Hepatic drain | Liver Cx | Survi-val | Hrs present. to death |
| 1 | Batge [ | 1992 | 61 | M | DM, pancreatic cancer s/p Whipple | 38.2 | 11.6 | 43.9 | + | Yes – p | – | Yes | N/A |
| 2 | Rogstad | 1993 | 61 | M | None | N/A | 16.7 | N/A | + | No | + (a) | No | 3 |
| 3 | Gutierrez | 1995 | 74 | M | None | 19.8 | 13.1 | 4.1 | + | No | + (a) | No | 6 |
| 4 | Jones | 1996 | 66 | F | Liver Transplant | 11.3 | 11.3 | 4.4 | + | No | + (a) | No | 10 |
| 5 | Eckel | 2000 | 65 | F | CBD CA meta s/p TACE | 13 | 11.2 | 4.6 | + | Yes – p | nr | Yes | N/A |
| 6 | Kreidl | 2002 | 80 | M | DM, ESRD on HD | 29 | 10.7 | 12.6 | + | No | + (a) | No | 11 |
| 7 | Pichon | 2003 | 42 | F | Alcohol cirrhosis | 6.2 | 10.2 | 12.3 | + | No | nr | Yes | N/A |
| 8 | Quigley | 2003 | 73 | M | Ischemic heart | 11 | 14.2 | 4.2 | nr | No | + (a) | No | Died at home |
| 9 | Bergert [ | 2004 | 58 | M | Pancreatic cancer s/p Whipple 1 yr | 34.1 | N/A | 7.7 | E. coli | Yes – p | + | No | 24 |
| 10 | Au | 2005 | 65 | M | DM, ESRD on HD | 25 | 6.2 | 9.4 | nr | No | + | No | 72 |
| 11 | Fondran | 2005 | 63 | M | pancreatic cancer meta to liver | N/A | N/A | N/A | + | Yes – O | nr | Yes | N/A |
| 12 | Daly | 2006 | 80 | M | DM | N/A | 8.7 | N/A | + | No | nr | No | 3 |
| 13 | Ohfani | 2006 | 78 | M | DM | 18.6 | 10 | 1.4 | + | No | + (a) | No | 3 |
| 14 | Loran | 2006 | 69 | M | None | 26 | 8.7 | N/A | nr | No | + (a) | No | 6 |
| 15 | Alarcon Del Agua | 2009 | 74 | M | Stroke | 16 | N/A | 3.7 | + | Yes – O | + | Yes | N/A |
| 16 | Merino | 2009 | 83 | F | None | 26.5 | 12.2 | 19.6 | + | No | nr | No | 72 |
| 17 | Meyns | 2009 | 64 | M | DM, myelodysplastic syndrome | 1.5 | 7.2 | 8.3 | + | Yes – p | + | No | 48 |
| 18 | Tabarelli | 2009 | 65 | F | pancreatic cancer s/p Whipple | N/A | N/A | N/A | + | Yes – p | + | No | 120 |
| 19 | Bradly [ | 2010 | 52 | M | HCC s/p RY HJ | 11.6 | N/A | 17.4 | + | No | + (a) | No | 6 |
| 20 | Ng | 2010 | 61 | F | DM | 16.8 | 13.5 | 15.4 | + | Yes – O | nr | Yes | N/A |
| 21 | Rajendran | 2010 | 58 | M | None | 14.6 | 13.3 | N/A | + | Yes – O | + | Yes | N/A |
| 22 | Law [ | 2012 | 50 | F | Rectal Cancer | 46.3 | 8.3 | 8.9 | + | Yes – p | nr | No | 168 |
| 23 | Qandeel | 2012 | 59 | F | DM, s/p cholecystectomy | N/A | 9.1 | N/A | + | Yes – O | nr | Yes | N/A |
| 24 | Sathiyam-oorthy | 2012 | 65 | F | DM | N/A | N/A | N/A | + | Yes – p | nr | Yes | N/A |
| 25 | Imai | 2014 | 76 | M | HTN | 33.2 | 12.2 | 10.5 | + | Yes – p | + | No | 5 |
| 26 | Kitterer | 2014 | 71 | M | Liver Transplant | 18.5 | 11.2 | 3.7 | + | Yes – O | nr | No | 13 |
| 27 | Kurasawa | 2014 | 65 | M | DM | 24.8 | 13.5 | 6.4 | + | No | nr | No | 6 |
| 28 | Cochrane | 2015 | 65 | F | DM | normal | 13 | 9.6 | + | Yes – p | nr | Yes | N/A |
| 29 | Eltawansy | 2015 | 81 | F | Stroke | 22 | N/A | 0.4 | + | Yes – p | + | No | 120 |
| 30 | Khan | 2015 | 77 | M | DM, HTN | 33 | 6 | 9.5 | – | No | + (a) | No | 7 |
| 31 | Li | 2015 | 71 | M | HCC s/p TACE | 11.5 | 11.8 | 18.9 | + | No | nr | Yes | N/A |
| 32 | Rives | 2015 | 63 | M | Colon CA meta to liver. ERCP for obs. Jaundice | 21.3 | N/A | 7.6 | + | Yes – p | nr | Yes | N/A |
| 33 | Garcia | 2016 | 65 | M | DM, Chiari I | 22.2 | 14.6 | 2.6 | + | Yes – p | + | Yes | N/A |
| 34 | Hashiba | 2016 | 82 | M | DM | 30.1 | 8.3 | 9 | + | No | nr | No | 2 |
| 35 | Kyang [ | 2016 | 84 | M | gastric cancer meta to liver s/p MW ablasion | 4 | N/A | N/A | E. coli | Yes – p | + | Yes | N/A |
| 36 | Lim | 2016 | 58 | M | None | 14.2 | 12.4 | N/A | + | No | nr | No | 7.5 |
| 37 | Shen | 2017 | 65 | M | DM | 32 | 12 | 7.8 | + | Yes – O | S. c. | No | 264 |